lenalidomide has been researched along with Refractory Anemia in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bewersdorf, JP; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Wang, X; Zeidan, AM; Zhang, C | 1 |
| Beguin, Y; Caberg, JH; Caers, J; Hafraoui, K; Keutgens, A; Lambert, F; Tassin, F | 1 |
| Patnaik, MM; Tefferi, A | 1 |
| de Wolf, JT; Huls, G; Mulder, AB; Rosati, S; van de Loosdrecht, AA; Vellenga, E | 1 |
| Chmarzyńska, E; Dwilewicz-Trojaczek, J; Jędrzejczak, WW; Koperski, Ł; Pastwińska, A; Paszkowska-Kowalewska, M; Ziarkiewicz, M; Ziarkiewicz-Wróblewska, B | 1 |
| He, Y; Li, W; Li, X; Liu, F; Liu, X; You, Y; Zhang, M; Zheng, J; Zou, P | 1 |
| Buresh, A; Fuchs, D; Heaton, R; Knight, R; Kurtin, S; List, A; Mahadevan, D; Rimsza, L; Roe, DJ; Zeldis, JB | 1 |
| Eclache, V; Fenaux, P; Kelaidi, C | 1 |
2 review(s) available for lenalidomide and Refractory Anemia
| Article | Year |
|---|---|
Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Topics: Anemia, Refractory; Anemia, Sideroblastic; Angiogenesis Inhibitors; Aspirin; Female; Humans; Iron Overload; Janus Kinase 2; Lenalidomide; Male; Mutation; Myelodysplastic Syndromes; Phosphoproteins; Platelet Aggregation Inhibitors; Receptors, Thrombopoietin; Ribonucleoprotein, U2 Small Nuclear; Risk Factors; RNA Splicing Factors; Thalidomide; Thrombocytosis | 2015 |
The role of lenalidomide in the management of myelodysplasia with del 5q.
Topics: Anemia, Refractory; Antineoplastic Agents; Chromosome Deletion; Chromosomes, Human, Pair 5; Cytogenetics; Humans; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Thalidomide; Treatment Outcome | 2008 |
1 trial(s) available for lenalidomide and Refractory Anemia
| Article | Year |
|---|---|
Efficacy of lenalidomide in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Anemia, Refractory; Angiogenesis Inhibitors; Bone Marrow; Female; Gene Deletion; Hematopoiesis; Humans; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2005 |
5 other study(ies) available for lenalidomide and Refractory Anemia
| Article | Year |
|---|---|
Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States.
Topics: Aged; Anemia, Refractory; Chromosome Deletion; Chromosomes, Human, Pair 5; DNA; Humans; Lenalidomide; Medicare; Methyltransferases; Myelodysplastic Syndromes; Thalidomide; Treatment Outcome; United States | 2021 |
Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
Topics: Aged, 80 and over; Anemia, Refractory; Bone Marrow; Erythrocytes, Abnormal; Female; Humans; Immunologic Factors; Lenalidomide; Thalidomide; Thrombocytosis; Treatment Outcome | 2014 |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Aged, 80 and over; Anabolic Agents; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Erythropoietin; Humans; Hypertension, Pulmonary; Janus Kinase 2; Lenalidomide; Male; Middle Aged; Mutation; Pulmonary Embolism; Pyridoxine; Reverse Transcriptase Polymerase Chain Reaction; Thalidomide; Thrombocytosis; Vitamin B Complex | 2010 |
Refractory anaemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T) with superimposed 5q-syndrome.
Topics: Aged; Anemia, Macrocytic; Anemia, Refractory; Anemia, Sideroblastic; Antineoplastic Agents; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Therapy, Combination; Humans; Hydroxyurea; In Situ Hybridization, Fluorescence; Lenalidomide; Male; Thalidomide; Thrombocytosis | 2010 |
Response to lenalidomide of a patient with t(2;3)(p23;q29) and JAK2 non-mutated refractory anemia with ring sideroblasts and thrombocytosis.
Topics: Adult; Anemia, Refractory; Bone Marrow; Chromosomes, Human, Pair 2; Chromosomes, Human, Pair 3; Female; Humans; Janus Kinase 2; Karyotype; Lenalidomide; Thalidomide; Thrombocytosis; Translocation, Genetic; Treatment Outcome | 2013 |